Analysis index

1 ml serum (Stability in serum at 4° C – 8° C: 4 days)

Lying down: 29 – 145 ng/l (80 – 400 pmol/l)

Sitting up: 65 – 285 ng/l (180 – 790 pmol/l)

Children: Please refer to findings report

Unclear electrolyte disorders (hypernatremia and hyponatremia, hyperkalemia and hypokalemia), suspicion of primary hyperaldosteronism (Conn syndrome), incidentalomas

A reliable assessment is impossible without simultaneous renin determination. Additional renin determination is imperative in the diagnostics regarding primary hyperaldosteronism (Conn syndrome) to determine the aldosterone-renin quotient (ARQ).

Some antihypertensive drugs may influence the findings and should be considered when interpreting the aldosterone value remotely.

False positive results: Thiazide diuretics, loop diuretics and aldosterone receptor antagonists (such as spironolactone, eplerenone)

False negative results: Beta blockers, centrally effective alpha-1 inhibitors (such as clonidine), ACE inhibitors, AT-1 blockers (sartans), renin inhibitors (such as aliskiren).

Without influence on results: Calcium antagonists of the dihydropyridine type (such as amlodipine, nifedipine), calcium antagonists of the phenylalkylamine type (such as verapamil), peripheral alpha antagonists (such as doxazosin), dihydralazine. Therefore, antihypertensive drugs, which can lead to false negative and false positive results, should be discontinued a minimum of one week prior to determining the isolated aldosterone. Exceptions are aldosterone receptor antagonists, which have to be discontinued at least 4 weeks before the test.